6th mRNA‑Based Therapeutics Summit

With rapid advances in in vivo CAR‑T, gene editing, and cancer immunotherapy – alongside headline‑making acquisitions such as Eli Lilly & Orna, BMS & Orbital, AbbVie & Capstan, and BioNTech & CureVac – the mRNA field is entering a new era of scientific and commercial possibility.

Returning to Boston this summer, the 6th mRNA‑Based Therapeutics Summit brings together 350+ global experts at the forefront of mRNA discovery, development, and delivery. Featuring leaders from Moderna, Pfizer, AstraZeneca, Sanofi, ParcelBio, CaVos Therapeutics, Kernal Biologics, and key regulators including the US FDA, MHRA, and EMA, this summit is the premier meeting ground for those shaping the next generation of mRNA medicines.

With a refreshed three‑track agenda and new focus days dedicated to AI‑Driven mRNA Design and Next‑Gen Delivery Technologies, the event offers unparalleled insights, partnership opportunities, and strategic guidance to accelerate mRNA pipelines worldwide.

Dates: July 20-22, 2026

Location: The Westin Boston Seaport District

View Full Event Program: https://ter.li/8yxkym

Reserve your Ticket: https://ter.li/8yxkyv

What’s New for 2026?

Regulatory & Policy Insights – Experts from the European Medicines Agency and Moderna will share perspectives on achieving global regulatory harmonization to achieve mRNA commercial success across different products.
mRNA Leaders & Top CEOs – Hear directly from the leading players rewriting mRNA’s potential, including Moderna, BioNTech, Pfizer, Sanofi, CREATE Medicines, Eli Lilly, Circurna, Replicate Biosciences, and more.
Emerging Innovators Spotlight – 20+ pioneering startups and world-leading biotechs – including CaVos Biotherapeutics, Cambridge Medixine, RNAvate, and Particella – will present novel advances in linear mRNA, circular, and saRNA design, delivery, and cutting-edge R&D strategies.
Inaugural AI & mRNA Design Day – Explore predictive modeling and sequence engineering solutions accelerating mRNA development, with contributions from Kernal Biologics, Sanofi, and Abogen Bio.
Advancing In Vivo Cell Engineering – With in vivo cell engineering hitting the headlines, gain fresh insight into mRNA-LNP capabilities to advance cell therapy, featuring Parcel Bio, Inndura Therapeutics, Nava Therapeutics, and others.